Chicago Capital LLC Sells 83,481 Shares of Zoetis Inc. $ZTS

Chicago Capital LLC lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 25.4% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 244,850 shares of the company’s stock after selling 83,481 shares during the quarter. Chicago Capital LLC owned approximately 0.05% of Zoetis worth $38,184,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in ZTS. Lindbrook Capital LLC lifted its holdings in Zoetis by 1.8% during the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company’s stock valued at $612,000 after purchasing an additional 65 shares during the last quarter. Scott & Selber Inc. lifted its holdings in Zoetis by 0.6% during the second quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock valued at $1,817,000 after purchasing an additional 67 shares during the last quarter. Secure Asset Management LLC lifted its holdings in Zoetis by 2.9% during the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock valued at $382,000 after purchasing an additional 68 shares during the last quarter. Quotient Wealth Partners LLC lifted its holdings in Zoetis by 2.3% during the first quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company’s stock valued at $521,000 after purchasing an additional 72 shares during the last quarter. Finally, Broadway Wealth Solutions Inc. lifted its holdings in Zoetis by 4.4% during the first quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company’s stock valued at $287,000 after purchasing an additional 73 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ZTS shares. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Piper Sandler increased their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Argus reissued a “buy” rating and issued a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Stifel Nicolaus downgraded shares of Zoetis from a “buy” rating to a “hold” rating and lowered their price target for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Finally, Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Moderate Buy” and a consensus price target of $200.88.

Zoetis Stock Down 0.4%

Shares of Zoetis stock opened at $142.97 on Tuesday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $196.55. The stock has a market capitalization of $63.36 billion, a price-to-earnings ratio of 24.61, a P/E/G ratio of 2.30 and a beta of 0.88. The company’s 50 day moving average price is $150.26 and its 200-day moving average price is $155.52.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.